Markets
In this photo illustration, the Hims & Hers Health logo is...
(Thomas Fuller/Getty Images)

Hims & Hers to sell Eli Lilly’s Zepbound on its platform

Hims & Hers is unable to sell copies of GLP-1 agonists after the FDA declared the shortage of those drugs is over.

J. Edward Moreno
4/1/25 1:16PM

Hims & Hers shares rose Tuesday afternoon after the telehealth company said it would offer Eli Lilly’s blockbuster weight-loss drug Zepbound on its platform.

The move gives Hims & Hers a way to offer its users the cutting edge of popular weight-loss drugs after the FDA severely limited Hims’ ability to produce them itself. On February 21, the Food and Drug Administration announced an end to the shortage of semaglutide, the active ingredient in Ozempic and Wegovy, drugs made by Novo Nordisk. Hims & Hers made about $230 million selling compounded semaglutide in 2024. The company has never sold compounded tirzepatide, the active ingredient in Zepbound.

Hims & Hers users can now get a prescription for Zepbound on the platform, but not at a discount: it costs about $1,899 a month, according to the company’s website. Sometimes insured customers can be reimbursed for the drug. For comparison, Lilly offers Zepbound to uninsured patients for about $500 a month, and compounded semaglutide costs about $200 a month.

Shares initially jumped sharply on the news, but gains faded in the afternoon as investors parsed the news.

Hims & Hers share price tanked after the FDA announcement on February 21, as it became unclear to what extent the company could continue making money selling GLP-1 drugs. Even with the recent boost, which faded hours later, Hims & Hers is still significantly down since the FDA called off the shortage.

The company has previously said that it would sell generics of Novos older weight-loss drugs and personalized doses of semaglutide. We’re committed to bringing our customers more treatment options that best suit their needs, and we’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform, the company said in its announcement.

Lilly has struck deals to sell discounted vials of Zepbound on Ro, a privately held Hims & Hers competitor, and Amazon Pharmacy. Novo has launched its own direct-to-consumer platform to sell discounted Wegovy to patients without insurance.

More Markets

See all Markets
markets

Warner Bros. Discovery jumps after Wells Fargo ups price target on dealmaking buzz

Warner Bros. Discovery shares popped 7% Tuesday after Wells Fargo raised its price target on the media giant to $14 from $13 while keeping an equal-weight rating.

The bank’s optimism stemmed largely from the media giant’s potential for dealmaking. In June, WBD announced that it would split its operations into two companies, with the Streaming & Studios division (home to Warner Bros. Television, DC Studios, HBO, and Max) standing alone from the networks side (CNN, TNT Sports, and Discovery).

That separation could make the Streaming & Studios unit more attractive to buyers, the analysts said. They valued the segment at about $65 billion, which could translate to a takeover price north of $21 a share. Potential suitors range from Amazon and Apple to Sony and Comcast, though analysts flagged Netflix as the “most compelling” option despite its limited acquisition track record:

“While NFLX has historically not been acquisitive, [streaming and studios’] $12bn in annual content spend + library + 100+ acre studio lot offers a lot. It kickstarts a theatrical IP strategy, quickly scales video games and most importantly provides premium content to members.”

At Goldman Sachs’ Communacopia + Technology Conference this week, CEO David Zaslav also highlighted growing traction at HBO Max and hinted at future crackdowns on password sharing.

WBD shares are up 26% year to date, and up more than 93% over the past 12 months.

markets

Duolingo up on bullish note, hopes for a user rebound

Duolingo rose by the most in nearly a month after an analyst note painted a more bullish picture of the gamified language-learning company despite a dearth of news otherwise.

A quick check-in with analysts covering the stock on Wall Street found most of them otherwise flummoxed on the reason behind the uptick Thursday.

Some, however, suggested the rise may reflect optimism that the company has been able to reverse a monthslong downturn in daily active user metrics — a slump that set in after a social media backlash to a somewhat artless LinkedIn post from the company about its AI first strategy.

The bullish analyst note, published Thursday by Citizens JMP, suggested Duolingo could be a big beneficiary from a change to Apple’s rules governing its App Store driven by a ruling on a federal antitrust case against the company. The analysts wrote:

Given “Apple’s recent changes to U.S. App Store rules that allow developers to steer payments to the web where fees are similar to typical credit card fees rather than Apple’s 30% fee for in-app purchases and 30% fee on subscriptions for the first year and 15% thereafter, we expect mobile app companies including Duolingo, Life360, and Grindr Inc. to unlock meaningful cost benefits.”

At any rate, the next big event on the company’s calendar is its Duocon 2025 conference on Tuesday, where analysts are hoping to hear more hard information on all of the above topics.

markets

Jeep maker Stellantis surges as CEO says the automaker is in productive tariff talks with the US

Shares of Jeep and Dodge maker Stellantis are up more than 8% in Thursday afternoon trading, following comments from the automaker’s new CEO, Antonio Filosa, at a European auto conference.

On tariffs, Filosa said that Stellantis has had a “very productive exchange of ideas” with the Trump administration on the company’s manufacturing footprint and that the environment around the levies is “getting clearer and clearer.”

The US is Stellantis’ top priority, according to Filosa, and the company has taken efforts to turn things around in the market, where its struggled with sales in recent years. To fuel the turnaround, Stellantis is bringing back its popular Jeep Cherokee, which it discontinued in 2023.

As of 12:45 p.m. ET, Stellantis’ trading volume was at more than 140% of its average over the past 30 days.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.